<div id="readability-page-1"><div><p>As global markets experience a mix of positive corporate earnings and rising consumer inflation, the tech sector continues to draw attention with indices like the Nasdaq Composite reaching new highs. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that not only demonstrate robust financial performance but also show resilience to economic fluctuations and adaptability in the face of evolving market conditions.</p><h3>Top 10 High Growth Tech Companies Globally</h3><table><tbody><tr><th>Name</th><th>Revenue Growth</th><th>Earnings Growth</th><th>Growth Rating</th></tr><tr><td>Gold Circuit Electronics</td><td>20.76%</td><td>25.89%</td><td>★★★★★★</td></tr><tr><td>Shanghai Huace Navigation Technology</td><td>24.51%</td><td>23.48%</td><td>★★★★★★</td></tr><tr><td>Pharma Mar</td><td>26.67%</td><td>43.29%</td><td>★★★★★★</td></tr><tr><td>Shengyi Electronics</td><td>26.23%</td><td>37.40%</td><td>★★★★★★</td></tr><tr><td>eWeLLLtd</td><td>24.95%</td><td>24.40%</td><td>★★★★★★</td></tr><tr><td>KebNi</td><td>20.56%</td><td>94.46%</td><td>★★★★★★</td></tr><tr><td>Global Security Experts</td><td>20.56%</td><td>28.04%</td><td>★★★★★★</td></tr><tr><td>CARsgen Therapeutics Holdings</td><td>81.53%</td><td>96.08%</td><td>★★★★★★</td></tr><tr><td>Elliptic Laboratories</td><td>36.33%</td><td>78.99%</td><td>★★★★★★</td></tr><tr><td>JNTC</td><td>55.45%</td><td>94.52%</td><td>★★★★★★</td></tr></tbody></table><p>Click here to see the full list of 745 stocks from our Global High Growth Tech and AI Stocks screener.</p><p>Let's review some notable picks from our screened stocks.</p><h2>Shanghai Film (SHSE:601595)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Shanghai Film Co., Ltd. is involved in film distribution and screening activities in China, with a market cap of CN¥14.03 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily from film distribution and screening activities within China. It operates with a market cap of CN¥14.03 billion, focusing on the entertainment sector.</p><p>Shanghai Film, despite recent challenges with a 20.4% drop in earnings last year, is poised for a robust recovery with projected annual earnings growth of 35.2%. This growth rate outpaces the Chinese market's average of 23.3%, underscoring the company's resilience and potential in the entertainment sector. With R&amp;D investments sharply focused on innovative content creation, evidenced by their significant spendings which bolstered their competitive edge in a rapidly evolving industry landscape, Shanghai Film demonstrates a promising trajectory. The firm also benefits from substantial one-off gains amounting to CN¥45M, enhancing its financial standing as it gears up for future expansions and more dynamic market engagement.</p><ul><li>Take a closer look at Shanghai Film's potential here in our health report.</li><li>Review our historical performance report to gain insights into Shanghai Film's's past performance.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/979b42f0-003e-4755-b0af-db38fd491944/chart/revenue-and-expenses-breakdown"/><figcaption>SHSE:601595 Revenue and Expenses Breakdown as at Jul 2025</figcaption></figure><h2>HAND Enterprise Solutions (SZSE:300170)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> HAND Enterprise Solutions Co., Ltd. offers ERP implementation consulting services in China and has a market cap of CN¥19.02 billion.</p><p><strong>Operations:</strong> The company specializes in ERP implementation consulting services within China. It focuses on providing tailored solutions to optimize business processes for its clients, contributing significantly to its revenue model.</p><p>HAND Enterprise Solutions has demonstrated a robust growth trajectory, with earnings forecasted to surge by 26.3% annually, outpacing the broader Chinese market's average of 23.3%. This performance is particularly notable given the firm's recent transition to profitability, which reflects positively on its operational efficiency and market adaptability. The company also maintains a solid commitment to shareholder returns as evidenced by its recent dividend affirmation, distributing a cash dividend of CNY 0.48 per share. Moreover, HAND's strategic focus on R&amp;D is evident from its allocation of significant resources towards innovation—ensuring it remains competitive in the dynamic tech landscape.</p><ul><li>Navigate through the intricacies of HAND Enterprise Solutions with our comprehensive health report here.</li><li>Assess HAND Enterprise Solutions' past performance with our detailed historical performance reports.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c577163e-dd8c-4766-90c7-04ff8893cfda/chart/revenue-and-expenses-breakdown"/><figcaption>SZSE:300170 Revenue and Expenses Breakdown as at Jul 2025</figcaption></figure><h2>Hualan Biological Vaccine (SZSE:301207)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Hualan Biological Vaccine Inc. focuses on the research, development, production, and sale of vaccines in China with a market cap of CN¥11.18 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily through its vaccine products, leveraging its expertise in research and development. Its focus on the Chinese market is supported by a robust production and sales infrastructure.</p><p>Hualan Biological Vaccine is navigating a transformative phase, marked by a robust revenue forecast growth of 36.1% annually, outstripping the broader Chinese market's expansion rate of 12.4%. Despite recent challenges such as a significant earnings dip last year and lower profit margins at 17.9% compared to 35% previously, the company's strategic amendments aim to bolster governance and operational agility. This proactive approach is complemented by an aggressive R&amp;D investment strategy, ensuring Hualan remains at the forefront of innovation in the biotech sector. With earnings expected to surge by 49.8% per year, these initiatives could position Hualan favorably within its competitive landscape.</p><ul><li>Get an in-depth perspective on Hualan Biological Vaccine's performance by reading our health report here.</li><li>Examine Hualan Biological Vaccine's past performance report to understand how it has performed in the past.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85c1c8b5-f8c4-4232-83d4-2d75422da5a7/chart/earnings-and-revenue-growth"/><figcaption>SZSE:301207 Earnings and Revenue Growth as at Jul 2025</figcaption></figure><h2>Summing It All Up</h2><ul><li>Click this link to deep-dive into the 745 companies within our Global High Growth Tech and AI Stocks screener.</li><li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li><li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li></ul><h2>Searching for a Fresh Perspective?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

002007

<p>As global markets see positive corporate earnings and rising consumer inflation, the tech sector is highlighted, with the Nasdaq Composite reaching new highs. Key high-growth tech companies include Gold Circuit Electronics, Shanghai Huace Navigation Technology, and Pharma Mar, showcasing strong revenue and earnings growth. Notable picks like Shanghai Film and HAND Enterprise Solutions demonstrate resilience and adaptability, with projected earnings growth outpacing market averages. Hualan Biological Vaccine is also positioned for significant growth, focusing on R&D and operational improvements. Investors are encouraged to explore these opportunities in the tech sector.</p>

High Growth Tech Stocks To Explore In July 2025